April 1, 2026: Patient Form Temporary Outage Notice – Patient forms will be unavailable tonight from 9:00 PM – 5:00 AM EST due to scheduled maintenance. Access will be restored on April 2, 2026, by 6:00 AM EST. Thank you for your patience.
A recombinant human-mouse chimeric monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody ALT-836 binds to TF or the TF-Factor VIIa (FVIIa) complex preventing binding and activation of Factor X (FX) and Factor IX (FIX). This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and procoagulant, is overexpressed in many tumor cell types, and is correlated with metastasis, angiogenesis, tumor growth and tumor-associated thrombosis. Check for active clinical trials using this agent. (NCI Thesaurus)